

February 2, 2016

BIONIK

# Bionik Laboratories to Present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016

**- Presentation with live webcast on Monday, February 8 at 1:30 p.m. EST -**

TORONTO, Feb. 2, 2016 /PRNewswire/ -- [Bionik Laboratories Corp.](#) (OTCQX: BNKL), a pioneering medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders ("Bionik" or the "Company"), announced today that [Peter Bloch, Chief Executive Officer](#) and Chairman of the Board, will present at the [18<sup>th</sup> Annual BIO CEO & Investor Conference](#) on Monday, February 8, 2016 at 1:30 p.m. EST in New York, NY.



**BIONIK**  
LABORATORIES

Mr. Bloch will present a corporate overview and provide an update on the progress of its primary product, [ARKE™](#), [a robotic lower-body exoskeleton device](#) designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking and other motion. Bionik expects to report key verification and clinical data on ARKE from testing in Canadian rehabilitation centers in mid-2016. The Company's growth strategy focused on acquiring, licensing and partnering synergistic products and technologies to

enhance its internal product pipeline will also be discussed.

A live webcast of the presentation will be available on Bionik's [IR Calendar](#) in the [Investor Relations](#) section of the Company's website ([www.bioniklabs.com](http://www.bioniklabs.com)). The webcast replay will be available approximately two hours after the presentation ends and will be archived for 30 days.

### **About BIO**

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The [18<sup>th</sup> Annual BIO CEO & Investor Conference](#) is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies. Each year the conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. BIO also produces the [BIO International Convention](#), the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

### **About Bionik Laboratories**

Bionik Laboratories (OTCQX: BNKL) is a pioneering medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders. The Bionik team has researched, developed and tested its primary product, ARKE™, a robotic lower-body exoskeleton device designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking and other motion. For more information, please visit [www.bioniklabs.com](http://www.bioniklabs.com) and connect with the Company on [Twitter](#), [LinkedIn](#), [Facebook](#), and [Google+](#).

### **Forward-Looking Statements**

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired

results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.

Logo - <https://photos.prnewswire.com/prnh/20150817/258751LOGO>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/bionik-laboratories-to-present-at-the-18th-annual-bio-ceo--investor-conference-on-february-8-2016-300212801.html>

SOURCE Bionik Laboratories Corp.